Charting a Bold Path for 2025
Exciting times are ahead for Camber Pharmaceuticals in 2025!
We are on track to launch up to 55 new generic medications, including several Day-One products, specialty drugs, and over-the-counter (OTC) medications. Additionally, we are continuing our investment in portfolio expansion, critical infrastructure, and associate development to create an even more significant impact.
To learn more, please watch this short message from Camber’s management team!
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection